References
- Morales J, Brown SM, Abdul-Rahim AS, et al. Ocular effects of apraclonidine in Horner syndrome. Arch Ophthalmol. 2000;118:951–954.
- Bacal D, Levy S. The use of apraclonidine in the diagnosis of Horner syndrome in pediatric patients. Arch Ophthalmol. 2004;122:276–279.
- Watts P, Satterfield D, Lim MK. Adverse effects of apraclonidine used in the diagnosis of Horner syndrome in infants. J Aapos. 2007;11:282–283.
- Wright T, Freedman S. Exposure to topical apraclonidine in children with glaucoma. J Glaucoma. 2009;18:395–398.
- Becker ML, Huntington N, Woolf AD. Brimonidine tartrate poisoning in children: frequency, trends, and use of naloxone as an antidote. Pediatrics 2009;123:e305–ee31.
- Yuksel N, Güler C, Çaglar Y, et al. Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers. Int Ophthalmol 1992;16:337–342.
- Eddy O, Howell J. Are one or two dangerous? Clonidine and topical imidazolines exposure in toddlers. J Emerg Med. 2003;25:297–302.
- van Velzen AG, van Riel AJHP, Hunault C, et al. A case series of xylometazoline overdose in children. Clin Toxicol (Phila). 2007;45:290–294.
- Saunders NR, Liddelow SA, Dziegielewska KM. Barrier mechanisms in the developing brain. Front Pharmacol. 2012;3:46.
- Seger DL, Loden JK. Naloxone reversal of clonidine toxicity: dose, dose, dose. Clin Toxicol (Phila). 2018;56:873–879.